Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) announced Monday that it has engaged H.C. Wainwright & Co., LLC (“H.C. Wainwright & Co.”) to assist the Company in exploring and evaluating a range of strategic and financial alternatives, intended to maximize shareholder value. The Company has advanced several late stage development programs in the field of dermatology, including the Company’s lead product candidate, SB206, that is in Phase 3 clinical trials for molluscum contagiosum (“molluscum”), a primarily pediatric contagious skin infection. In addition, Novan has initiated several early stage programs in women’s health and gastrointestinal (“GI”) disorders.
Read the full article: Novan Announces Comprehensive Evaluation of Strategic and Financial Alternatives //
Source: https://www.globenewswire.com/news-release/2020/04/20/2018865/0/en/Novan-Announces-Comprehensive-Evaluation-of-Strategic-and-Financial-Alternatives.html